Evotec

EVO

Market cap $1.13B

Milestone payment reflects continued progress under strategic research collaboration addressing high-need patient populations FDA clearance of IND application triggered a US$ 5 m milestone payment to Evotec HAMBURG, DE / ACCESS Newswire / November 12, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that it has received a US$ 5 m milestone payment from Bristol Myers Squibb, following the acceptance of an Investigational New Drug ("IND") application by the U.S. Food and Drug Administration ("FDA") in their strategic protein degradation partnership. The drug candidate, a cereblon E3 ligase modulator ("CELMoD™") was developed under the collaboration, and a Phase 1 clinical trial is expected to begin in 2026.

Evotec SE ( EVO ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Volker Braun - Executive VP and Head of Global Investor Relations & ESG Christian Wojczewski - CEO & Management Board Member Paul Hitchin - CFO & Member of Management Board Cord Dohrmann - Chief Scientific Officer & Member of Management Board Conference Call Participants Charles Weston - RBC Capital Markets, Research Division Brendan Smith - TD Cowen, Research Division Fynn Scherzler - Deutsche Bank AG, Research Division Presentation Operator Ladies and gentlemen, welcome to the Evotec SE Quarterly Statement 9M 2025 Conference Call. I'm Lorenzo, the Chorus Call operator.

Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business Strong scientific advancements of co-developed asset pipeline: Expecting up to four molecules in clinical phase II in next six to nine months Signing of landmark industry transaction with Sandoz on 04 November, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules 2025 guidance and 2028 outlook confirmed HAMBURG, DE / ACCESS Newswire / November 5, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced its business update for 9M 2025, illustrating the ongoing systematic execution of its strategy. In the D&PD segment, the market for early drug discovery services remained soft, while strategic partnerships are on track and Evotec records strong progress in its partnered asset pipeline.

Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology Accelerated implementation of strategy through better monetization of technology and transitioning to an asset-lighter business model Agreement includes approximately US$ 350 m in cash for Just - Evotec Biologics manufacturing site in Toulouse and upfront technology license fees to Evotec's continuous manufacturing platform In addition, Evotec eligible for license fees, and development revenues including success-based milestones adding up to more than US$ 300 m over the coming years, replacing existing contractual commitments Transaction covering royalties on a portfolio of up to ten biosimilars in technical and early development targeting more than US$ 90 bn of originator net sales Sale immediately earnings accretive, improving Evotec's short, mid and long-term revenue mix, profit margins, and capital efficiency HAMBURG, GERMANY / ACCESS Newswire / November 4, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO), a life science company that is pioneering the future of drug discovery and development, today announced the successful signing of the sale of the Just - Evotec Biologics Toulouse site to Sandoz AG (SIX:SDZ)(OTCQX:SDZNY), a global leader in generic and biosimilar medicines. Under the landmark transaction, Sandoz will acquire 100% of Just - Evotec Biologics EU plus an indefinite technology license to Evotec's continuous manufacturing platform technology for a payment of approximately US$ 350 m in cash.

HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

Advances made in preclinical pipeline addressing neurodegenerative diseases Evotec receives US$ 25 m payment to support continued progression of joint programs HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that the Company has received a payment of US$ 25 m from Bristol Myers Squibb (NYSE: BMY) for scientific progress achieved within their strategic neuroscience partnership. The payment will advance further research and the partners' joint pipeline of programs aimed at tackling neurogenerative diseases.

Evotec SE (NASDAQ:EVO ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Christian Wojczewski - CEO & Management Board Member Cord Dohrmann - Chief Scientific Officer & Member of Management Board Paul Hitchin - CFO & Member of Management Board Volker Braun - Executive VP and Head of Global Investor Relations & ESG Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Charles Robert Weston - RBC Capital Markets, Research Division Christian Ehmann - Warburg Research GmbH Douglas Dylan Tsao - H.C. Wainwright & Co, LLC, Research Division Fynn Scherzler - Deutsche Bank AG, Research Division Joseph Hedden - Rx Securities Limited, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Operator Ladies and gentlemen, welcome to the Evotec SE Half Year Report 2025 Conference Call.

Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect strategic focus Group revenues of € 371.2 m (-5%); D&PD (-11%) continues to see soft demand;Just - Evotec Biologics ("JEB"; +16%) exceeding expectations driven by broadened customer base Key progress in collaborations with Bristol Myers Squibb ("BMS") on targeted protein degradation and neuroscience Evolution of strategic partnership with Sandoz announced on 30 July HAMBURG, DE / ACCESS Newswire / August 13, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced financial results for H1 2025, demonstrating clear progress in the implementation of its new strategy for sustainable and profitable growth; highlighting Just - Evotec Biologics' strong growth as it transitions to an asset-lighter model. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "We are firmly on track with the execution of our strategy: Evotec is making meaningful strides toward sustainable and profitable growth.

HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.

HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration, future development revenues, milestones and product royalties.